Veraxa Biotech AG (VRXA)
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment.
$1.83-0.07%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-82.4%
The outlook
Veraxa Biotech AG currently reads as bearish based on below its 50- & 200-day averages, 1% of the way from its 52-week low to high. This is a snapshot of current market data, not a forecast.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range1% of the way from its 52-week low to high
Market cap
$258.8M
52-wk high
$27.36
52-wk low
$1.70
50-day avg
$6.58
200-day avg
$9.92
Trailing P/E
—